The Swiss giant signs an agreement with the biotech Enterome in food allergies.
Nestlé takes a further step in medicine. The Swiss giant, known for its KitKat, Buitoni and Nescafé brands, has just entered into a partnership with the French biotech Enterome, which specializes in microbiota, in order to market drugs against food allergies and inflammatory bowel diseases. “Around 220 million people worldwide suffer from food allergies and 7 million from inflammatory bowel disease, comments Hans-Juergen Woerle, Medical Director of Nestlé Health Science, Nestlé’s health subsidiary. Through this collaboration, we intend to develop treatments in these two areas whose unmet medical needs remain very high..»
The first drug resulting from this agreement should enter clinical development next year. Enterome, founded in 2012 within the bosom of Inra (National Institute for Agronomic Research, now Inrae) and the Seventure fund, will have to develop…
This article is for subscribers only. You have 71% left to discover.
Cultivating your freedom is cultivating your curiosity.
Keep reading your article for €0.99 for the first month
Already subscribed? Login